Koers Gentian Diagnostics AS Oslo Bors
Aandelen
NO0010748866
Medische apparatuur, benodigdheden & distributie
Omzet 2024 * | 174 mln. 16,04 mln. 14,9 mln. | Omzet 2025 * | 226 mln. 20,77 mln. 19,29 mln. | Marktkapitalisatie | 595 mln. 54,74 mln. 50,84 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 7 mln. 644K 598K | Nettowinst (verlies) 2025 * | 13 mln. 1,2 mln. 1,11 mln. | EV/omzet 2024 * | 3,05 x |
Nettoliquiditeiten 2024 * | 63 mln. 5,79 mln. 5,38 mln. | Nettoliquiditeiten 2025 * | 65 mln. 5,98 mln. 5,55 mln. | EV/omzet 2025 * | 2,35 x |
K/w-verhouding 2024 * |
77,6
x | K/w-verhouding 2025 * |
44
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 54,85% |
Recentste transcriptie over Gentian Diagnostics AS
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Hilja Ibert
CEO | Chief Executive Officer | - | 16-07-18 |
Njaal Kind
DFI | Director of Finance/CFO | 52 | 02-01-18 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Settevik
CHM | Chairman | 64 | - |
Fredrik Thoresen
BRD | Director/Board Member | 44 | - |
Director/Board Member | 60 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,89% | 12,56 mld. | |
-9,59% | 7,68 mld. | |
-1,31% | 5,29 mld. | |
+21,82% | 5,18 mld. | |
+0,02% | 4,57 mld. | |
-50,89% | 3,29 mld. | |
+6,42% | 2,6 mld. | |
-10,02% | 2,2 mld. | |
-8,29% | 1,79 mld. |